Learn Peptides. Get the Best Price.

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191) studied for fat metabolism and weight loss. It mimics GH's lipolytic effects without affecting blood sugar or growth. Previously in clinical trials for obesity; now popular in research settings.

Cagrilintide is Novo Nordisk's long-acting amylin analog designed for weight management. Phase 2 trials showed 11.8% body weight loss as monotherapy and up to 17.1% when combined with semaglutide (CagriSema). Works by enhancing satiety and slowing gastric emptying through amylin receptor activation.

Liraglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management. The first GLP-1 approved for weight loss, it produces 5-10% body weight reduction. Requires daily injection due to its ~13 hour half-life, but has the longest safety track record among GLP-1 medications.

Melanotan I (Afamelanotide) is a synthetic analog of alpha-MSH that stimulates melanin production for skin tanning and photoprotection. FDA-approved for erythropoietic protoporphyria (EPP), a rare genetic condition causing extreme sun sensitivity. More selective than Melanotan II with a cleaner side effect profile.

Melanotan II is a synthetic peptide that stimulates melanin production (tanning) and has effects on sexual function and appetite. More potent than Melanotan I with additional effects on libido. Not FDA-approved; used in research settings.

PTD-DBM is a cell-penetrating peptide that promotes hair growth by inhibiting CXXC5, a negative regulator of the Wnt/β-catenin signaling pathway. By blocking CXXC5-Dishevelled interaction, it activates Wnt signaling which is essential for hair follicle development and cycling. Research shows it can stimulate new hair growth and increase hair follicle size. Often used topically or via microneedling for androgenetic alopecia and hair thinning.

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials showed unprecedented 24% weight loss at the highest dose — the most ever recorded for any obesity medication. Currently in Phase 3 clinical trials, it represents the next generation of metabolic therapies.

Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management. It reduces appetite, slows gastric emptying, and improves insulin sensitivity, producing 15-20% weight loss in clinical trials. Administered as a once-weekly injection due to its ~7 day half-life.

Tirzepatide is the first dual GIP/GLP-1 receptor agonist, FDA-approved for type 2 diabetes and weight management. Its dual mechanism produces superior weight loss (20-25% in trials) compared to GLP-1-only medications. Administered once weekly with powerful effects on appetite, blood sugar, and body composition.